Pharvaris N.V. (PHVS)
NASDAQ: PHVS · Real-Time Price · USD
15.70
-0.10 (-0.63%)
Mar 31, 2025, 2:29 PM EDT - Market open
Pharvaris Employees
Pharvaris had 82 employees as of December 31, 2023. The number of employees increased by 17 or 26.15% compared to the previous year.
Employees
82
Change (1Y)
17
Growth (1Y)
26.15%
Revenue / Employee
n/a
Profits / Employee
-$1,798,233
Market Cap
851.46M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 82 | 17 | 26.15% |
Dec 31, 2022 | 65 | 31 | 91.18% |
Dec 31, 2021 | 34 | 20 | 142.86% |
Dec 31, 2020 | 14 | 11 | 366.67% |
Dec 31, 2019 | 3 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
PHVS News
- 4 weeks ago - Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress - GlobeNewsWire
- 4 weeks ago - Pharvaris to Participate in the Leerink Partners Global Healthcare Conference 2025 - GlobeNewsWire
- 2 months ago - Pharvaris Outlines 2025 Strategic Priorities - GlobeNewsWire
- 4 months ago - Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates - GlobeNewsWire
- 4 months ago - Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference - GlobeNewsWire
- 5 months ago - Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings - GlobeNewsWire
- 5 months ago - Pharvaris to Host Virtual Investor Event on October 23, 2024 - GlobeNewsWire
- 6 months ago - Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop - GlobeNewsWire